Bank Massad and Altshuler join TASE

Bank Massad Ltd., a unit of Bank Hapoalim and Altshuler Shaham, an investment house, have both joined as friends of the Tel Aviv Stock Exchange, in order to directly trade on the exchange.

By SHARON WROBEL
February 6, 2006 07:07

 
X

Dear Reader,
As you can imagine, more people are reading The Jerusalem Post than ever before. Nevertheless, traditional business models are no longer sustainable and high-quality publications, like ours, are being forced to look for new ways to keep going. Unlike many other news organizations, we have not put up a paywall. We want to keep our journalism open and accessible and be able to keep providing you with news and analyses from the frontlines of Israel, the Middle East and the Jewish World.

As one of our loyal readers, we ask you to be our partner.

For a symbolic $5 a month you will receive access to the following:

  • A user uxperience almost completely free of ads
  • Access to our Premium Section and our monthly magazine to learn Hebrew, Ivrit
  • Content from the award-winning Jerusalem Repor
  • A brand new ePaper featuring the daily newspaper as it appears in print in Israel

Help us grow and continue telling Israel’s story to the world.

Thank you,

Ronit Hasin-Hochman, CEO, Jerusalem Post Group
Yaakov Katz, Editor-in-Chief

UPGRADE YOUR JPOST EXPERIENCE FOR 5$ PER MONTH Don't show it again

Bank Massad Ltd., a unit of Bank Hapoalim and Altshuler Shaham, an investment house, have both joined as friends of the Tel Aviv Stock Exchange, in order to directly trade on the exchange. Massad, which provides services to the retail sector and in particular to teachers, has 12 branches across the country serving 70,000 customers. The bank, which has NIS 8.8 billion in assets under its management, said the membership would provide better services to its customers. Altshuler Shaham, which manages total assets worth about NIS 5b., specializes in the management of investment portfolios, mutual and provident funds.


Related Content

The Teva Pharmaceutical Industries
April 30, 2015
Teva doubles down on Mylan, despite rejection

By GLOBES, NIV ELIS